Uncomplicating the futureSM
 
Search

Healthcare Professionals

   Print page  Email page

Don’t Let Adhesions Block the Way

Adhesions are a common result of surgery — with potentially serious consequences:

  • Risk of complications for patients, including infertility1, chronic pelvic pain2, and reoperation for adhesive small bowel obstruction.3
  • Complications during future surgeries, including risk of inadvertent damage to organs and tissues, due to the need for extensive adhesiolysis.4
  • Compromised conditions for effective intraperitoneal chemotherapy5, pelvic radiotherapy6, and future laparoscopy.5

SEPRAFILM Adhesion Barrier is proven safe and effective in reducing adhesions in abdominopelvic laparotomy. No adhesion barrier has been more extensively evaluated in abdominopelvic surgery.7 In a clinical trial, patients treated with SEPRAFILM showed a 48% relative reduction in adhesions and were 8.5 times more likely to be adhesion-free as compared to untreated controls.8 Studies also show that SEPRAFILM reduced adhesion-related morbidities at reoperation.9,10

With more than 1 million patients treated and more than 10 years of clinical use, you can feel confident about SEPRAFILM. Learn how SEPRAFILM Adhesion Barrier can help prevent adhesions in your surgical practice.


1.  DiZerega GS.  Peritoneal repair and postsurgical adhesion formation. In: Management of Common Problems in Obstetrics & Gynecology. Mishell DR, Goodwin Murphy T, Brenner PF, eds. Malden, MA: Blackwell Publishing; 2002: 267-271.
 
10. Kusunoki M, Ikeuchi H, Yanagi H, et al. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today. 2005;35:940-945.
 
2. Keltz MD, Gera PS, Olive DL.  Prospective randomized trial of right-sided paracolic adhesiolysis for chronic pelvic pain. JSLS. 2006;10(4):443-446.
 
3. Ellis H, Moran BJ, Thompson JN, Parker MC, Wilson MS, Menzies D, et al.  Adhesion-related hospital readmissions after abdominal and pelvic surgery:  a retrospective cohort study. Lancet1999;353(9163):1476-1480.
 
4. Van der Krabben AA, Dijkstra FR, Nieuwenhuijzen M, Reijnen MMPJ, Schaapveld M, van Goor H.  Morbidity and mortality of inadvertent enterotomy during adhesiotomy. Br J Surg. 2000;87(4):467-471.
 
5. Nichols DH, Clarke-Pearson DL, eds. Gynecologic, Obstetric, and Related Surgery. 2nd ed. St. Louis, MO: Mosby, Inc; 1993.
 
5. Nichols DH, Clarke-Pearson DL, eds. Gynecologic, Obstetric, and Related Surgery. 2nd ed. St. Louis, MO: Mosby, Inc; 1993.
 
6. Eifel PF.  Radiation therapy. In: Berek JS, Hacker NF, eds. Practical Gynecologic Oncology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 119-161.
 
7. Data on file: Genzyme Biosurgery.
 
8. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183:297-306.
 
9. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision. Dis Colon Rectum. 2003;46:1200-1207.
 

 

 

Important Safety Information

Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy. The type and frequency of adverse events reported are consistent with events typically seen following surgery when used as directed. Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events. For important safety information, please see package insert.

Terms and Conditions of Use | Privacy Policy | Contact Us | This site is intended for United States residents only © 2002-2008 Genzyme Corporation. All rights reserved. Seprafilm and Genzyme are registered trademarks of Genzyme Corporation. genzyme logo